Bimatoprost grenod is under clinical development by NicOx and currently in Phase III for Open-Angle Glaucoma. According to GlobalData, Phase III drugs for Open-Angle Glaucoma have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bimatoprost grenod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bimatoprost grenod overview
NicOx is an ophthalmology company developing solutions to help maintain vision and improve ocular health. The company carries out the research, development and marketing of investigational drugs for ophthalmological diseases. The company aims to produce therapeutic products which aim to address the needs of eye care practitioners and patients. The company’s product pipeline includes NCX 470 for glaucoma and VYZULTA, ZERVIATE and NCX 4251 for blepharitis and dry eye disease. The company has a presence across Germany, France, the United Kingdom, Italy and Spain. NicOx is headquartered in Valbonne, France.
For a complete picture of Bimatoprost grenod’s drug-specific PTSR and LoA scores, buy the report here.